Bovespa Index Ends the Week 2.83% Lower at 131065.44 — Data Talk
The Bovespa Index is down 3816.51 points or 2.83% this week to 131065.44
--Largest one-week point and percentage decline since the week ending May 24, 2024
--Down two of the past three weeks
--Today it is down 2057.23 points or 1.55%
--Largest one-day point and percentage decline since Friday, June 7, 2024
--Down for four consecutive trading days
--Down 4052.78 points or 3.00% over the last four trading days
--Largest four-day point and percentage decline since Monday, April 15, 2024
--Longest losing streak since Tuesday, Sept. 3, 2024, when the market fell for four straight trading days
--Off 4.57% from its record close of 137343.96 hit Wednesday, Aug. 28, 2024
--Lowest closing value since Friday, Aug. 9, 2024
--Off 4.57% from its 52-week high of 137343.96 hit Wednesday, Aug. 28, 2024
--Up 16.47% from its 52-week low of 112531.52 hit Monday, Oct. 30, 2023
--Rose 12.98% from 52 weeks ago
--Off 4.57% from its 2024 closing high of 137343.96 hit Wednesday, Aug 28, 2024
--Up 10.01% from its 2024 closing low of 119137.86 hit Monday, June 17, 2024
--Month-to-date it is down 3.63%
--Year-to-date it is down 3119.80 points or 2.32%
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 20, 2024 17:19 ET (21:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk